Crinetics Pharmaceuticals Inc [CRNX] stock is trading at $59.09, up 0.29%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CRNX shares have gain 11.20% over the last week, with a monthly amount glided 9.67%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] stock has seen the most recent analyst activity on March 06, 2024, when Citigroup initiated its Buy rating and assigned the stock a price target of $68. Previously, Morgan Stanley started tracking the stock with Overweight rating on January 16, 2024, and set its price target to $50. On December 21, 2023, Jefferies initiated with a Hold rating and assigned a price target of $35 on the stock. Oppenheimer started tracking with a Outperform rating for this stock on August 31, 2023, and assigned it a price target of $40. In a note dated April 24, 2023, Piper Sandler initiated an Overweight rating and provided a target price of $56 on this stock.
Crinetics Pharmaceuticals Inc [CRNX] stock has fluctuated between $25.75 and $59.68 over the past year. Currently, Wall Street analysts expect the stock to reach $70.14 within the next 12 months. Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] shares were valued at $59.09 at the most recent close of the market. An investor can expect a potential return of 18.7% based on the average CRNX price forecast.
Analyzing the CRNX fundamentals
Gross Profit Margin for this corporation currently stands at -0.27% with Operating Profit Margin at -201.43%, Pretax Profit Margin comes in at -186.67%, and Net Profit Margin reading is -186.67%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.63 and Total Capital is -0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 58.39 points at the first support level, and at 57.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 59.79, and for the 2nd resistance point, it is at 60.50.
Ratios To Look Out For
For context, Crinetics Pharmaceuticals Inc’s Current Ratio is 16.09. Also, the Quick Ratio is 16.09, while the Cash Ratio stands at 5.56.
Transactions by insiders
Recent insider trading involved Pizzuti Dana, Chief Med and Dev Officer, that happened on Oct 03 ’24 when 14375.0 shares were sold. Officer, DANA J PIZZUTI completed a deal on Oct 03 ’24 to buy 14375.0 shares. Meanwhile, CFO Wilson Marc sold 25000.0 shares on Sep 26 ’24.
